Aripiprazole
Product Images NDC 50090-4817

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-4817). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig1 (Aripiprazole Fig 1)

A chart depicting the effect of other drugs on Aripiprazole, showing fold change and 90% confidence intervals for pharmacokinetic parameters AUC and Cmax. The chart compares changes relative to a reference without interacting drugs for various inhibitors, inducers, gastric acid blockers, and other drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

Fig2 (Aripiprazole Fig 2)

A pharmacokinetic chart illustrating the effect of various drugs on Aripiprazole. It shows the fold change and 90% confidence intervals for dehydro-Aripiprazole's area under the curve (AUC) and maximum concentration (Cmax) relative to a reference without an interacting drug. Drugs evaluated include CYP3A4 inhibitors and inducers, CYP2D6 inhibitors, gastric acid blockers, and others.*

FDA Label Image

Fig3 (Aripiprazole Fig 3)

A forest plot illustrating the fold change and 90% confidence intervals for pharmacokinetic parameters such as AUC and Cmax. The plot compares these changes relative to a reference condition without interacting drugs, showing results for various drugs including dextromethorphan, S-warfarin, R-warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and O-desmethylvenlafaxine.*

FDA Label Image

Fig4 (Aripiprazole Fig 4)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' displaying fold changes with confidence intervals for special populations. Categories compared include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, measuring changes in AUC and Cmax relative to a reference.*

FDA Label Image

Fig5 (Aripiprazole Fig 5)

A chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing fold changes in pharmacokinetic parameters (AUC and Cmax) relative to reference for various factors: CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. Data points with confidence intervals are plotted along a horizontal axis labeled 'Change Relative to Reference' ranging approximately from 0 to 3.*

FDA Label Image

Fig6 (Aripiprazole Fig 6)

A Kaplan-Meier survival curve chart comparing the proportion with relapse over days from randomization between Aripiprazole and placebo groups. The X-axis represents days from randomization, and the Y-axis shows the proportion with relapse. The chart includes numbers of subjects at risk at various time points for both groups.*

FDA Label Image

Str (Aripiprazole Str)

Chemical structure of Aripiprazole showing its molecular composition including two chlorine atoms, a piperazine ring, and a quinolinone moiety.*

FDA Label Image

Label Image (Lbl500904817)

Aripiprazole 15 mg tablet label from A-S Medication Solutions. The label shows product number 6702-0, NDC 50090-4817-0, storage instructions to keep at 68 to 77 degrees Fahrenheit, and a quantity of 30 tablets. The active ingredient is listed as Aripiprazole USP 15 mg. The label also includes a QR code and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.